Related Experiment Video
Updated: Jun 23, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Cysteamine Suppresses Cancer Cell Invasion and Migration in Glioblastoma through Inhibition of Matrix
Jinkyu Jung1, Orieta Celiku1, Benjamin I Rubin2
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Glioblastoma (GBM) cells are highly invasive, infiltrating the surrounding normal brain tissue, thereby limiting the efficacy of surgical resection and focal radiotherapy. Cysteamine, a small aminothiol molecule that is orally bioavailable and approved for cystinosis, has potential as a cancer treatment by inhibiting tumor cell invasion and metastasis. Here we demonstrate that these potential therapeutic effects of cysteamine are likely due to the inhibition of matrix metalloproteinases (MMPs) in GBM. In vitro assays confirmed that micromolar concentrations of cysteamine were not cytotoxic, enabling the interrogation of the cellular effects without confounding tumor cell loss. Cysteamine's inhibition of MMP activity, especially the targeting of MMP2, MMP9, and MMP14, was observed at micromolar concentrations, suggesting the mechanism of action in suppressing invasion and cell migration is by inhibition of these MMPs. These findings suggest that achievable micromolar concentrations of cysteamine effectively inhibit cancer cell invasion and migration in GBM, supporting the potential for use as an adjunct cancer treatment.
Insights
Cysteamine effectively inhibits glioblastoma cell invasion and migration by targeting matrix metalloproteinases (MMPs). This orally available drug shows promise as an adjunct cancer treatment without cytotoxicity at therapeutic doses.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Glioblastoma (GBM) exhibits high invasiveness, hindering surgical and radiotherapy effectiveness.
- Cysteamine, an orally bioavailable drug, is explored for its anti-cancer potential.
- Tumor cell invasion and metastasis are key challenges in GBM treatment.
Purpose of the Study:
- To investigate the mechanism by which cysteamine inhibits glioblastoma cell invasion.
- To determine if cysteamine's effects are mediated through matrix metalloproteinases (MMPs).
- To assess the non-cytotoxic concentrations of cysteamine for therapeutic potential.
Main Methods:
- In vitro assays to evaluate cysteamine's cytotoxicity.
- Analysis of cysteamine's effect on MMP activity in GBM cells.
- Quantification of MMP inhibition at specific cysteamine concentrations.
Main Results:
- Micromolar concentrations of cysteamine were not cytotoxic to GBM cells.
- Cysteamine significantly inhibited MMP activity, particularly MMP2, MMP9, and MMP14.
- Inhibition of MMPs correlated with reduced GBM cell invasion and migration.
Conclusions:
- Cysteamine's anti-invasive effects in GBM are likely mediated by MMP inhibition.
- Achievable micromolar concentrations of cysteamine suppress GBM cell invasion and migration.
- Cysteamine holds potential as an adjunctive therapy for glioblastoma.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:35Cancer Cell Migration through Invadopodia
01:10Drugs that Destabilize Microtubules
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...